DB
GYRE icon

Dmitry Balyasny’s Gyre Therapeutics GYRE Stock Holding History

Dmitry Balyasny’s Portfolio GYRE Stock Details GYRE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-13,979
Closed -$244K – 2775
2024
Q1 		$244K Buy
+13,979
New +$252K ﹤0.01% 2333

Other funds holding GYRE

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return
Charles Schwab
Charles Schwab San Francisco, California $751B AUM 38.74% 1-Year Est. Return
WG
Winton Group London, United Kingdom $3.09B AUM 40.4% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return

Dmitry Balyasny's GYRE Position: Q2 2024 in Review

Dmitry Balyasny sold out of Gyre Therapeutics (GYRE) in Q2 2024, closing a stake of 13,979 shares — an estimated $244K sold.

Dmitry Balyasny first reported a position in GYRE in Q1 2024 and held it in 1 quarter. The position peaked at $244K in Q1 2024. 30 funds tracked by Wall St. Rank hold GYRE as of Q2 2024.

  • Dmitry Balyasny reported no remaining Gyre Therapeutics position as of Q2 2024 after selling out during the quarter.
  • Dmitry Balyasny sold 13,979 Gyre Therapeutics shares in Q2 2024, an estimated $244K.
  • Dmitry Balyasny first reported a position in Gyre Therapeutics in Q1 2024 and held it in 1 quarter.
  • Dmitry Balyasny's Gyre Therapeutics position peaked at $244K in Q1 2024.
  • 30 funds tracked by Wall St. Rank held Gyre Therapeutics as of Q2 2024.

Based on Balyasny Asset Management's 13F filing for Q2 2024, filed 14 Aug 2024.